Royal London Asset Management Ltd. Has $141.73 Million Holdings in Halozyme Therapeutics, Inc. $HALO

Royal London Asset Management Ltd. boosted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 12.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,810,815 shares of the biopharmaceutical company’s stock after purchasing an additional 200,262 shares during the quarter. Royal London Asset Management Ltd. owned about 1.60% of Halozyme Therapeutics worth $141,732,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Bank of America Corp DE acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth about $214,504,000. William Blair Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at approximately $196,540,000. Norges Bank acquired a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at approximately $128,201,000. Jupiter Topco LLC bought a new position in Halozyme Therapeutics during the 2nd quarter worth approximately $105,570,000. Finally, Caisse de depot et placement du Quebec bought a new position in Halozyme Therapeutics during the 2nd quarter worth approximately $83,940,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on HALO. TD Cowen upped their target price on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $83.00 to $110.00 in a report on Friday, August 7th. Wells Fargo & Company raised their price target on Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. UBS Group reiterated a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Finally, Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $91.20.

Halozyme Therapeutics Trading Down 1.5%

Shares of NASDAQ:HALO opened at $105.35 on Friday. The firm has a market cap of $11.96 billion, a price-to-earnings ratio of 31.45, a PEG ratio of 0.43 and a beta of 0.85. Halozyme Therapeutics, Inc. has a 12 month low of $61.22 and a 12 month high of $109.66. The company’s fifty day simple moving average is $87.01 and its 200 day simple moving average is $74.78. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. During the same period in the prior year, the business earned $1.54 EPS. The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, research analysts forecast that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 1,626 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the transaction, the director owned 40,418 shares in the company, valued at $4,154,970.40. This trade represents a 3.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $79,987,320.40. This represents a 2.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 64,103 shares of company stock worth $5,226,496 in the last three months. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.